Contents

November 2011 • Volume 5 Number 4

3 Editorial comment
   Tracy Crooks

4 Direct patient ADR reporting: how is it relevant to the pharmaceutical industry?
   Despite concerns expressed by health professionals and pharmaceutical companies, direct patient reporting of adverse effects has led to a significant number of relevant and trustworthy reports.
   Janet Krska and Tony Avery

8 The impact of electronic prescribing on adverse drug events and medication risk
   Using computer systems has been shown to reduce medication errors and improve reporting of adverse events.
   Stephen Goundrey-Smith

11 Systems biology and drug regulation
   New scientific discoveries in genomics, imaging and bioinformatics can increase the accuracy of tests to improve the safety and efficacy of drugs in development, particularly paediatric drugs and drug combinations.
   Judith Farrés, Juan Bigorra and Jordi Naval

13 De-identification of electronic health records for genomic research
   De-identification of data is a means of facilitating disclosure of genomic data to researchers. The author describes and analyses the various methods.
   Khaled El Emam

19 Practical considerations for preparing Development Safety Update Reports (DSUR)
   The authors provide practical guidance to help companies produce periodic reports useful to Sponsors, Regulators and Ethics Committees.
   Sue Rees and Stewart Geary